Prostate Cancer — Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Citation(s)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)